Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
Official title: Towards characterization of Epigenetic targets in Prostate Cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-11573812 · Data updated 2026-11-12
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | March 1, 2025 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $350,285 |
| NIH project number | 7R01CA299870-03 |
| Project ID | NIH-11573812 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are men with prostate cancer where AR signaling and epigenetic cofactors play a role in disease progression.
✕Less likely to help
Patients whose cancer is not driven by AR signaling or epigenetic cofactors may not benefit from this research.
What this research studies
This project focuses on prostate cancer, especially forms that no longer respond to standard hormone therapies. Researchers will study AR-related cofactors and chromatin proteins that help cancer cells keep growing. By identifying and characterizing these epigenetic players, the work aims to reveal new targets for therapies that could work when current anti-androgen drugs fail. The study builds on prior findings about NSD2 and its role in prostate cancer progression. Results could guide future treatments that disrupt AR-driven transcription in patients.
Why it matters
Potential benefit: If successful, the work could lead to new therapeutic targets to combat resistant prostate cancer and improve outcomes for patients.
How similar studies have gone: Other studies linking epigenetic regulators to AR signaling have shown promising leads, suggesting this approach is worth pursuing but results are still evolving.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Asangani, Irfan Ahmed — University of Tx Md Anderson Can Ctr
- Study coordinator: Asangani, Irfan Ahmed
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
-
New microfluidic platform to test prostate cancer drugs using patient tumor cells
A new microfluidic, open platform uses patient-derived prostate cancer cells to create multi-culture tumor models that could better predict whether a treatment will work for Veterans.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.